Abstract: Clozapine (CLZ), as a unique and effective atypical antipsychotic drug, has achieved good results in the treatment of schizophrenia, but its cardiotoxicity has attracted the attention of clinicians. Clozapine-induced myocarditis (CIM) is a rare but serious cardiovascular adverse event during the use of clozapine, the pathogenesis of which is unknown. The picture is further complicated by considering that people with schizophrenia may have cognitive impairments that make early heart damage difficult to detect. Therefore, this review summarizes the clinical manifestations, auxiliary examination characteristics, risk factors and possible pathogenesis of CIM, providing clues for doctors to diagnose, monitor and treat the CIM.